Retraction to: Glypican 1 Stimulates S Phase Entry and DNA Replication in Human Glioma Cells and Normal Astrocytes (Molecular and Cellular Biology, (2013), 33, 22, (4408-4421), 10.1128/MCB.00238-13);Glypican 1 stimulates S phase entry and DNA replication in human glioma cells and normal astrocytes

Molecular and Cellular Biology

Volumn 33, Issue 22, 2013, Pages 4408-4421

  Qiao, Dianhua ^a   Meyer, Kristy ^a   Friedl, Andreas ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIP KIP CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DIMETHYL SULFOXIDE; DNA; GLYPICAN 1; MITOGEN ACTIVATED PROTEIN KINASE; NOCODAZOLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT GROWTH FACTOR; REPLICATION LICENSING FACTOR CDT1; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANEUPLOIDY; ARTICLE; ASTROCYTE; CARCINOGENESIS; CELL ACTIVATION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; G1 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MITOGENICITY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SERUM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

EID: 84887014126     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00321-16     Document Type: Erratum

References (45)

1. Holland EC. 2000. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. U. S. A. 97:6242-6244.
2. Wen PY, Kesari S. 2008. Malignant gliomas in adults. N. Engl. J. Med. 359:492-507.
3. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64:7011-7021.
4. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nature genetics. 25:55-57.
5. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP. 2011. The origins of glioma: e pluribus unum? Glia 59:1135-1147.
6. Bonavia R, Inda MM, Cavenee WK, Furnari FB. 2011. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 71:4055- 4060.
7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683-2710.
8. Huse JT, Holland EC. 2010. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10:319-331.
9. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110.
10. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA. 2008. p53 and Pten control neural and glioma stem/ progenitor cell renewal and differentiation. Nature 455:1129-1133.
11. Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A. 2006. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 168:2014-2026.
12. Fico A, Maina F, Dono R. 2011. Fine-tuning of cell signaling by glypicans. Cell. Mol. Life Sci. 68:923-929.
13. Jen YH, Musacchio M, Lander AD. 2009. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural development. 4:33.
14. Litwack ED, Ivins JK, Kumbasar A, Paine-Saunders S, Stipp CS, Lander AD. 1998. Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent. Dev. Dynam. 211:72-87.
15. Qiao D, Meyer K, Friedl A. 2012. Glypican-1 stimulates Skp2 autoinduction loop and G1/S transition in endothelial cells. J. Biol. Chem. 287: 5898-5909.
16. Qi W, Martinez JD. 2003. Reduction of 14-3-3 proteins correlates with increased sensitivity to killing of human lung cancer cells by ionizing radiation. Radiat Res. 160:217-223.
17. Davidson IF, Li A, Blow JJ. 2006. Deregulated replication licensing causes DNA fragmentation consistent with head-to-tail fork collision. Mol. Cell 24:433-443.
18. Sclafani RA, Holzen TM. 2007. Cell cycle regulation of DNA replication. Annu. Rev. Genet. 41:237-280.
19. Symeonidou IE, Taraviras S, Lygerou Z. 2012. Control over DNA replication in time and space. FEBS Lett. 586:2803-2812.
20. Ma D, Zhou P, Harbour JW. 2003. Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J. Biol. Chem. 278:19358-19366.
21. Johnson DG, Walker CL. 1999. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39:295-312.
22. Yung Y, Walker JL, Roberts JM, Assoian RK. 2007. A Skp2 autoinduction loop and restriction point control. J. Cell Biol. 178:741-747.
23. Starostina NG, Kipreos ET. 2012. Multiple degradation pathways regulate versatile CIP/KIP CDK inhibitors. Trends Cell Biol. 22:33-41.
24. Castro A, Bernis C, Vigneron S, Labbe JC, Lorca T. 2005. The anaphasepromoting complex: a key factor in the regulation of cell cycle. Oncogene 24:314-325.
25. Nakayama KI, Nakayama K. 2005. Regulation of the cell cycle by SCFtype ubiquitin ligases. Semin. Cell Dev. Biol. 16:323-333.
26. Vodermaier HC. 2004. APC/C and SCF: controlling each other and the cell cycle. Curr. Biol. 14:R787-796.
27. Truong LN, Wu X. 2011. Prevention of DNA re-replication in eukaryotic cells. J. Mol. Cell Biol. 3:13-22.
28. Xouri G, Dimaki M, Bastiaens PI, Lygerou Z. 2007. Cdt1 interactions in the licensing process: a model for dynamic spatiotemporal control of licensing. Cell Cycle 6:1549-1552.
29. Malumbres M, Barbacid M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9:153-166.
30. Malumbres M, Ortega S, Barbacid M. 2000. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors. Biol. Chem. 381: 827-838.
31. Caron C, Boyault C, Khochbin S. 2005. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27:408-415.
32. Fransson LA, Belting M, Cheng F, Jonsson M, Mani K, Sandgren S. 2004. Novel aspects of glypican glycobiology. Cell. Mol. Life Sci. 61:1016- 1024.
33. Liang Y, Haring M, Roughley PJ, Margolis RK, Margolis RU. 1997. Glypican and biglycan in the nuclei of neurons and glioma cells: presence of functional nuclear localization signals and dynamic changes in glypican during the cell cycle. J. Cell Biol. 139:851-864.
34. Asundi VK, Keister BF, Carey DJ. 1998. Organization, 5=-flanking sequence and promoter activity of the rat GPC1 gene. Gene 206:255-261.
35. Lin H, Huber R, Schlessinger D, Morin PJ. 1999. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res. 59:807-810.
36. Boily G, Saikali Z, Sinnett D. 2004. Methylation analysis of the glypican 3 gene in embryonal tumours. Br. J. Cancer 90:1606-1611.
37. Engelbert D, Schnerch D, Baumgarten A, Wasch R. 2008. The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogene 27:907-917.
38. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. 2002. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr. Biol. 12:1817-1827.
39. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, Wagle N, Hwang DS, Dutta A. 2003. A p53-dependent checkpoint pathway prevents rereplication. Mol. Cell 11:997-1008.
40. Garcia-Higuera I, Manchado E, Dubus P, Canamero M, Mendez J, Moreno S, Malumbres M. 2008. Genomic stability and tumour suppression by the APC/C cofactor Cdh1. Nat. Cell Biol. 10:802-811.
41. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. 2004. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430:797-802.
42. Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE, Roberts JM. 2005. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8:35-47.
43. Seo J, Chung YS, Sharma GG, Moon E, Burack WR, Pandita TK, Choi K. 2005. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53. Oncogene 24:8176-8186.
44. Maddalena AS, Hainfellner JA, Hegi ME, Glatzel M, Aguzzi A. 1999. No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathol. 9:627-637.
45. Huse JT, Holland EC. 2009. Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol. 19:132- 143.